-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

605.Oral2.6 605. Molecular Pharmacology, Drug Resistance—Lymphoid and Other Diseases: Chronic Lymphocytic Leukemia and other Lymphoid Diseases

Molecular Pharmacology, Drug Resistance—Lymphoid and Other Diseases Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
apoptosis, Leukemia, Diseases, Adult, Non-Biological, Therapies, CLL, Mechanisms, Technology and Procedures, epigenetics, chemotherapy, Study Population, genomics, Lymphoid Malignancies, Clinically relevant, genetic testing, pharmacology, molecular testing, molecular interactions, NGS, signal transduction
Monday, December 11, 2017: 4:30 PM-6:00 PM
Bldg B, Lvl 2, B216-B217 (Georgia World Congress Center)
Moderators:
Tanya Siddiqi, MD, City of Hope National Medical Center and Matthew S. Davids, MD, Dana-Farber Cancer Institute
Disclosures:
Siddiqi: Seattle Genetics: Speakers Bureau; Juno: Other: Steering committee for JCAR017; Pharmacyclics, an AbbVie Company: Other: Steering committee for ibrutinib, Speakers Bureau. Davids: Gilead: Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Astra-Zeneca: Consultancy; Infinity: Consultancy, Research Funding; Celgene: Consultancy; Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; TG Therapeutics: Membership on an entity's Board of Directors or advisory committees, Research Funding; InCyte: Membership on an entity's Board of Directors or advisory committees; Pharmacyclics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Merck: Consultancy.
4:30 PM

Hannah R. Robinson, BA1,2, Junpeng Qi, PhD3*, Sivasubramanian Baskar, PhD1*, Erika Cook, BA1*, Inhye E. Ahn, MD4, Sarah E. M. Herman, PhD1*, Christoph Rader, PhD3* and Adrian Wiestner, MD1

1Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
2Cleveland Clinic Lerner College of Medicine, Cleveland, OH
3Department of Immunology and Microbiology, The Scripps Research Institute, Scripps Florida, Jupiter, FL
4National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD

4:45 PM

Gregory Ian Vladimer, PhD1*, Christian Schmidl, PhD1*, Andre Renderio, MS1*, Susanne Schnabl, MS2*, Tea Pemovska, PhD1*, Berend Snijder, PhD1,3*, Thomas Krausgruber, PhD1*, Nikolaus Krall, PhD1*, Mohammad Araghi2*, Rainer Hubmann2*, Anna Ringler1,4*, Dita Demirtas2*, Oscar Lopez de la Fuente, BSc1*, Martin Hilgrath2*, Cathrin Skrabs, MD2*, Edit Anna Porpaczy, MD2*, Michaela Gruber, MD, PhD1,2*, Gregor Hoermann, MD5, Stefan Kubicek, PhD1,4*, Philipp Bernhard Staber, MD, PhD2, Medhat M. Shehata, MD2*, Giulio Superti-Furga, PhD1,6*, Christoph Bock, PhD1,5,7* and Ulrich Jaeger, MD2*

1CeMM, Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
2Department of Medicine I, Division of Hematology and Hemostaseology, and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
3Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland
4Christian Doppler Laboratory for Chemical Epigenetics and Anti-Infectives, CeMM, Vienna, Austria
5Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
6Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria
7Max Planck Institute for Informatics, Saarland Informatics Campus, Saarbrücken, Germany

5:00 PM

Ya Zhang, MD1*, Xiangxiang Zhou, MD1*, Ying Li, MD1*, Yangyang Xu, MD1* and Xin Wang, MD, PhD1,2

1Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China
2School of Medicine, Shandong University, Jinan, China

5:15 PM

Joshua Gustine*, Kirsten Meid, MPH*, Toni Dubeau, NP*, Patricia Severns, NP*, Lian Xu*, Zachary Hunter, PhD, Steven P Treon, MD, PhD, FRCP and Jorge J. Castillo, MD

Bing Center for Waldenstrom's macroglobulinemia, Dana Farber Cancer Institute, Boston, MA

5:30 PM

Jiaji Chen, BS*, Xia Liu, MD*, Manit Munshi, MS*, Lian Xu*, Nickolas Tsakmaklis, BA*, Maria Demos, BS*, Amanda Kofides, BS*, Maria Luisa Guerrera, MD*, Gloria Chan, MS*, Zachary Hunter, PhD, Christopher Patterson, MAcc*, Joshua Gustine*, Jorge J. Castillo, MD, Steven P Treon, MD, PhD, FRCP and Guang Yang, PhD

Bing Center for Waldenstrom's macroglobulinemia, Dana Farber Cancer Institute, Boston, MA

5:45 PM

Katia Beider1*, Valeria Voevoda1*, Hanna Bitner1*, Evgenia Rosenberg1*, Yaarit Sirovsky1*, Hila Magen, MD1*, Olga Ostrovsky, PhD1*, Avichai Shimoni, MD1*, Zohar Bromberg, PhD2*, Amnon Peled3* and Arnon Nagler, MD4

1Chaim Sheba Medical Center, Ramat-Gan, Israel
2Hadassah Hebrew University Hospital, Jerusalem, Israel
3Goldyne Savad Institute of Gene Therapy, Hebrew University Hospital, Jerusalem, Israel
4Acute Leukemia Working Party of EBMT, Paris, France

*signifies non-member of ASH